Objectives: To estimate risk of comorbid depression on all-cause mortality over time among individuals with diabetes. Methods: The Medline, Cumulative Index to Nursing and Allied Health Literature, Cochrane Library, Embase and Science Direct databases were searched through September 30, 2012. We limited our search to longitudinal or prospective studies reporting all-cause mortality among those having depression and diabetes, compared with those having diabetes alone that used hazard ratios (HRs) as the main outcome. Two reviewers independently extracted primary data and evaluated the quality of studies using predetermined criteria. The pooled random effects adjusted HRs were estimated using meta-analysis. The impact of moderator variables on study effect size was examined with meta-regression. Results: A total of 42,363 respondents from 10 studies were included in the analysis. Depression was significantly associated with risk of mortality (pooled HR=1.50, 95% confidence interval=1.35-1.66). Little evidence for heterogeneity was found across the studies (Cochran Q=13.52, P=.20, I 2 =26.03). No significant possibility of publication bias was detected (Egger's regression intercept=0.98, P=.23). Conclusion: Depression significantly increases the risk of mortality among individuals with diabetes. Early detection and treatment of depression may improve health outcomes in this population.
Finally, we searched the Institute of Scientific Information Web of Science database for studies citing the eligible studies and reviewed their titles and abstracts to determine eligibility.
Selection criteria
To be included in the current analysis, a report needed to have a longitudinal or prospective study design, report all-cause mortality with hazard ratios (HRs) and include individuals with a measure of depression [self-report questionnaire, structured psychiatric interview, International Classification of Diseases, Ninth Revision (ICD-9) code or antidepressant prescription] and Type 1 or Type 2 diabetes (self-report, ICD-9 code, laboratory result or prescription of glucose lowering medication). We decided to have such broad inclusion criteria because we preferred to err on the side of inclusiveness. To maximize the generalizability of the results of the study, we excluded studies with special populations such as those with a specific complication of diabetes (such as a foot ulcer). We chose HRs to include the effect of depression on all-cause mortality among individuals with diabetes over time; this approach limited the analytic technique of the study to Cox regression [9] . We did not use relative risk (RR) or odds ratios (ORs) as proxy for HR in our analysis because these do not account for time in the calculation. Furthermore, some studies have shown that longer follow-up time increases the divergence between RR, OR and HR [9] . In the event of multiple publications, only the most recent manuscript was included.
Data extraction
M.P. and W.J.K. reviewed all the studies using a standardized data extraction form. Discrepancies were resolved by consensus. Primary data extracted for the current analyses included the method by which depression and diabetes were diagnosed, study design, sample size, setting, duration of the follow-up, outcome measures, covariates, HR and 95% confidence intervals (95% CIs). Our primary goal was to compare the risk of all-cause mortality between those with diabetes alone and those with comorbid depression and diabetes. Thus, when four group results were presented (no DM/depression, depression only, DM only and DM and depression), we calculated HRs of having both DM and depression relative to those with DM only using the method outlined by Altman and Bland [10] . If multiple risk estimates were presented in a given manuscript, we selected the estimate that most closely adjusted for demographic characteristics, behavioral risk factors, comorbidity and DM status. For studies that presented graded relationships (e.g., low, medium, high depressive symptoms), only the cutting scores that correlated the highest with a probable major depression diagnosis were used.
Assessment of validity
M.P. and W.J.K. independently rated each study on six components of quality with an instrument similar to that used by Grote et al. [11] . The components of quality included clarity of description of the study population, quality of diagnosis of depression, quality of diagnosis of diabetes, appropriateness of statistical test, percentage of successful recruitment of study population, adequacy of sample size, representativeness of study population, attrition rate reported and reflected statistically and number of key potential confounders adjusted for in multivariate analyses. The quality scores can range from 0 to 16; discrepancies between reviewers were resolved by consensus.
Data synthesis and statistical analysis
M.P. and F.M.W. performed analyses using Review Manager 5 [12] and Comprehensive Meta-Analysis [13] . The studies were weighted by the inverse variance methods described in the user's manual of the Comprehensive Meta-Analysis. We used both a random-effect model and a fixed-effect model to pool the study results [14] . We pooled adjusted HRs with a 95% CI [15] [16] [17] [18] . Values greater than 1 indicate an unfavorable impact of depression on mortality. Forrest plots [19] of the estimates and 95% CIs, with the weight of each point estimate indicated by the relative size of the marker, were used to visually examine the range of effects. The heterogeneity of effect sizes was assessed using the Cochran Q statistic (Q-value) and the I 2 statistic. A P value smaller than .01 was considered evidence of significant heterogeneity [20] . Higher I 2 values (ranging between 0% and 100%) indicate greater variability among the studies than would be expected by chance alone [21] .
Using meta-regression [22] , we examined the impact of the following moderator variables on study effect size: study populations (community vs. clinical population), duration of follow-up, study site (U.S. vs. non-U.S.), age and gender of the majority of subjects, number of observations and quality scores of the report. We also conducted leave-one-out analyses [23] for each study to examine the magnitude of influence of each study on pooled mortality. Publication bias was assessed using funnel plot, Egger's test [24, 25] , Duval and Tweedie's trim-and-fill approach [26] and classic fail-safe N [27].
Results

Study selection (Fig. 1)
The EndNote computer software was used to store search results, organize them and identify duplicate citations. We identified 1236 records from the initial search. After duplicates were identified and removed, 775 potentially relevant unique articles were retrieved. One author (M.P.) reviewed and excluded 700 manuscripts that did not refer to depression, diabetes or mortality in the title. When in doubt whether to exclude or include a study based on the title, we included the study for abstract review. Abstracts of the remaining 75 studies were reviewed and 23 articles were selected for full text review. One report that was currently under review in a peer-reviewed journal was identified by an expert researcher and one additional record was identified through bibliographic review. Two authors (M.P. and W.J.K.) independently reviewed manuscripts. One study treated depression scores as a continuous variable without a cutpoint; we unsuccessfully contacted the first author of the study for additional analyses so that we could include the study in our analysis. Nine reports published in English [28] [29] [30] [31] [32] [33] [34] [35] [36] and one in German [37] were included in the meta-analysis. Fig. 1 presents the overall search flow. Table 1 shows the main characteristics of the studies. The characteristics of the 13 studies excluded from the analysis [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] and the reasons for exclusion appear in Table 2 .
Participants
A total of 42,363 respondents with DM were included in this meta-analysis. Among them, 5325 individuals had both depression and DM and the remaining 37,038 cases had a diagnosis of DM alone. The number of depression and DM cases in each study ranged between 52 and 1657, whereas the number of DM only cases in each study ranged between 401 and 13,694. Six out of 10 studies recruited study samples from the community, and other studies used hospital or other primary care clinic settings. Seven studies analyzed data from mixed-age populations and three studies used older adult populations.
Measurement of depression and diabetes
Depression was measured by self-reported scales such as the Center for Epidemiologic Studies Depression Scale (CES-D), Patient Health Questionnaire-9 (PHQ-9), ICD-9 code or antidepressant use.
Depression measures were dichotomized with a cutoff point. Two studies measured depression with CES-D with a cutoff point of 16 [28, 29] , two studies used the PHQ-9 diagnosis of major depression [33, 35] , two studies used ICD-9 codes [31, 32] and the other two studies used other symptom severity instruments [30, 37] . One study used purchase of antidepressant as proxy for depression [36] . The baseline depression status was included in the current meta-analysis. To diagnose diabetes, five studies used blood tests [30, 32, 33, 36, 37] , two studies used patient self-report [28, 29] and questionnaire [34] , two studies used ICD-9 codes [31, 32] and one study used filled prescription of insulin or an oral hypoglycemic agent as DM indicator [33] . Whereas other studies examined individuals with Type 2 DM or combined individuals with Type 1 and Type 2 DM, Ahola et al. [36] studied individuals with Type 1 DM only.
Study outcomes
All studies reported adjusted HRs for all-cause mortality and four studies also reported adjusted HRs for cardiovascular mortality. Ahola et al. [36] reported the results for women and for men separately. We treated these results as separate studies, instead of calculating pooled HRs. The mean length of follow-up varied from 2 to 10 years. Five studies reported data for 5 years or longer.
Statistics and covariates
All studies used Cox-regression models. Nine studies reported the crude number of deaths or OR in addition to HR. All results were adjusted for sociodemographic characteristics, and nine studies also included covariates such as health behaviors (e.g., smoking and physical activity) and clinical characteristics (e.g., comorbidity or Charlson comorbidity score, diabetes complications) in the analysis. However, specific characteristics adjusted for varied among the studies. (Table 3 and Fig. 2 
Effect of depression on mortality among those with diabetes
)
Depression was significantly associated with increased risk of mortality (pooled HR=1.48, 95% CI=1.36-1.61). Little evidence for significant heterogeneity was found across the studies (Cochran Q= 13.52, P= .20, I 2 =26.03). Four studies reported risk of cardiovascular mortality in addition to all-cause mortality. Using a random-effect model, depression was significantly associated with increased risk of cardiovascular mortality (pooled HR=1.21, 95% CI=1.05-1.37). We found little evidence for significant heterogeneity in cardiovascular mortality across the studies (Cochran Q=3.96, P= .41, I 2 = 0%).
Sensitivity tests
We conducted three tests to examine the degree of robustness of the above results. First, we compared the random-effect and fixedeffect models and did not find a significant difference in pooled HR between the two (fixed model pooled HR=1.48, 95% CI=1.36-1.60 vs. random model pooled HR=1.50, 95% CI=1.35-1.66) ( Table 3 ). The leave-one-out analyses found that no single report unduly influenced the pooled risk ratio estimates of the association between depression and all-cause mortality among those with diabetes. Finally, we conducted a series of random-effect single covariate meta-regression analyses to examine how each moderator is associated with the pooled HR. We calculated regression coefficients to describe the differences in HRs between the groups categorized by covariate and P value of the coefficient to examine whether there is a linear relationship between HRs and the covariate. Moderators examined include location of study (the U.S. vs. the non-U.S.), quality scores, sampling frame (community vs. hospital/clinic), length of follow-up, gender of the majority of sample (majority women vs. majority men), age of sample (older adults vs. mixed-age) and the number of observations. No significant moderating effects were found.
Publication bias
We first visually inspected the funnel plots [25] , in which each study's effect size was plotted against the standard error. The asymmetry suggested that small studies with negative results might not have been published. Duval and Tweedie's trim-and-fill analysis [26] suggested that two studies were missing in the left side of the mean effect. The imputed HR using the trim-and-fill approach was 1.46 (95% CI=1.30-1.63), which was slightly lower than our estimation. The result of Egger's regression intercept approach [24] indicated no significant evidence of publication bias (intercept=0.99; two-tailed 95% CI, − 0.74 to 2.72; P=.23). The result of classic fail-safe N [27] suggested that 230 nil or null reports would be needed to raise the P value associated with the average effect above an alpha level .05. The fail-safe N value is larger than the recommended 5k+10 limit (= 60) [52] . The results of these four tests indicated that it is unlikely that publication bias poses a significant threat to the validity of findings reported in the current analysis. Fig. 3 presents the results of testing for publication bias.
Discussion
Comorbid depression in respondents with diabetes was associated with an approximately 1.5-fold increase in risk of mortality among the individuals with diabetes. Little evidence of heterogeneity was found across studies and the results were consistent across several sensitivity analyses including the leave-one-out analysis and the analysis that compared random-effect and fixed-effect models. Moreover, results were also consistent when examining several potential moderators including geographic location of study, gender, community vs. hospital/clinic populations, age of population, length of follow-up and qualities of the studies. Comorbid depression was also associated with an approximately 20% higher risk of cardiovascular mortality in these respondents with diabetes in the four studies examining specific cause of death.
The results of the current analyses are consistent with the existing literature [53] , and to our knowledge, this study is the first metaanalysis to estimate risk of all-cause mortality associated with comorbid depression among individuals with diabetes. Two studies that did not meet the inclusion criteria because of examining only subgroups of patients with DM who had specific complications were excluded from this meta-analysis but also found increases in mortality among those with comorbid depression and DM [38, 39] . Ismail et al. [38] and Bot et al. [39] examined individuals with their first diabetesrelated foot ulcer and those with after myocardial infarction, respectively. Both studies concluded that comorbid depression increased mortality in these patient groups with diabetes complications (adjusted HR=2.73, 95% CI=1.38-5.40 and adjusted HR=2.10, 95% CI=1.32-3.35, respectively). Furthermore, the greater risk of mortality in these patients with significant diabetes complications compared to the risk found in the above systematic review suggests that the risk of comorbid depression for mortality may be higher among those with greater severity of disease. Depression may contribute to negative DM outcomes in several ways. Katon [54] proposed a complex bidirectional relationship between depression and Type 2 DM. Depression early in adult life is a risk factor for subsequent development of diabetes [55] . The increased risk of diabetes in patients with depression has been hypothesized to be the result of maladaptive health risk behaviors associated with depression such as smoking, obesity and lack of physical exercise [54] as well as psychobiologic factors such as increased cortisol levels, increased inflammatory factors [56] and insulin resistance [57] . On the other hand, diabetes may increase risk of depression or worsen the depression symptoms due to increased symptom burden, diabetes complications causing functional impairment and decreased quality of life, as well as vascular brain changes secondary to diabetes. Comorbid depression has been found to impair the ability to perform self-care activities necessary to control diabetes by affecting memory, energy level and executive function. Lack of selfcare and the psychobiologic changes associated with depression may explain why individuals with comorbid depression experience increased risk of macro-and micro-vascular complications [58] and dementia [59] . Two publications allowed examination of whether clinical characteristics (such as severity of diabetes and other medical comorbidity) or health risk behaviors potentially mediated the risk of depression on mortality: Lin et al. [33] and Pieper et al. [37] . When clinical characteristics (such as number of diabetes complications) were added to the models that initially only adjusted for demographic characteristics, there was a decrease in point estimates of the HRs. However, adding covariates related to health risk behaviors [such as smoking, body mass index (BMI), physical inactivity and HbA 1c ] into the previous models resulted in little change in the point estimates. This suggests that the mechanism for the relationship between depression and excess mortality in individuals with diabetes may be largely psychobiological. As discussed earlier, because these covariates are not uniform across the studies, head-to-head comparisons are not possible. Further studies are sorely needed to have meaningful conclusion about the mechanism of excess mortality associated with depression in individuals with diabetes.
Prior literature found an approximately twofold increase of mortality in patients with comorbid depression and each of the following chronic medical conditions: stroke [60] , coronary heart disease [53] , cancer [61] and chronic obstructive pulmonary disease [62] . The current meta-analysis and literature support the finding that comorbid depression increases the risk of mortality among those with chronic disease. However, whether depression alone decreases life expectancy is controversial. Reynolds et al. [46] reported that depression symptoms reduced total life expectancy significantly but controlling for chronic diseases eliminated the effect of depression symptoms on mortality across age and gender groups. In contrast, Cuijpers and Smit's meta-analysis of community studies [63] concluded that having depression increased overall mortality by almost twofold. However, their results did not control for lifestyle factors or the presence of chronic conditions. This systematic review of the literature revealed several major important gaps in knowledge. Although some minority populations experience an increased prevalence of both depression and diabetes and a disproportionate burden of these illnesses [64] [65] [66] , few epidemiological studies provide conclusive data whether minority populations experience greater mortality burden from comorbid depression and DM compared to other populations. Among the 10 studies included in the current analysis, the study by Black et al. [28] was the only one that reported the mortality risk associated with comorbid depression and DM in a large aging Hispanic population. They reported a higher risk of mortality associated with depression and diabetes in this population compared to the other studies. However, their study only adjusted for demographic characteristics whereas the other studies also controlled for important other potential confounders including health risk behaviors and disease severity. There are also no studies in developing countries that have examined the risk of comorbid depression in patients with Type 2 diabetes. Studies of diverse populations and in developing countries are urgently needed to draw conclusions about potential disparities in mortality burden associated with depression among minority patients with diabetes. Additionally, studies on Type 1 diabetes are also needed. DM is a heterogeneous metabolic disease with distinctive etiology and requirements for disease management. Thus, psychological reactions to onset of disease and burdens of disease may differ between Type 1 and Type 2 DM. However, both Type 1 and Type 2 DM require constant monitoring and self-management. Depression adversely affects a person's ability to optimally perform these functions and may increase mortality in individuals with DM regardless of the type. In the current analysis, only the study of Ahola et al. [36] examined populations with Type 1 diabetes. Other community-based or primary-care-based studies examined populations with Type 2 DM only or those where over 90% of the sample were likely to have Type 2 DM.
Considering the frequent multi-morbidity found in aging adult populations, early intervention and treatment of depression may be particularly important to improve mortality outcomes. Yet there is limited data about whether screening and treating depression more effectively would decrease premature death associated with DM. A recent report [48] has found that older adults with depression and diabetes who received more effective depression treatment in primary care settings experienced a decrease in 5-year mortality rates compared to those received usual primary care (adjusted HR= 0.49, 95% CI=0.24-0.98). However, three other studies that enhanced depression care and improved depressive outcomes compared to usual primary care in patients with diabetes and depression did not find a significant decrease in mortality [67] [68] [69] . This was not an priori hypothesis in these three studies that were likely underpowered to examine mortality outcomes.
Limitations
The results of the current analyses should be interpreted in the context of some limitations. First, despite our best efforts to capture all publications that meet the criteria, we may have missed some studies published in journals that are not indexed in the databases where we conducted searches, those published in non-journal venues or studies that have not been published. However, our results regarding publication bias suggest that publication bias in very unlikely to have affected our findings. Secondly, we pooled the adjusted HRs from the studies reviewed using different covariates. As seen in Table 1 , we categorized covariates into three groups. However, each category was defined differently across the studies. Despite the evidence for strong associations between mortality and characteristics such as severity of diabetes, other comorbid conditions and health behaviors, not all studies adjusted for all these covariates. Such variation in control for potential confounders may have reduced compatibility of the studies and introduced noise into our estimation. Nonetheless, the lack of heterogeneity and negligible differences in the pooled adjusted HRs in the random-effect and fixed-effect models both suggest that these differences in controlling for potential confounders across studies is unlikely to have effected our findings.
Conclusion
The results of this meta-analysis provide robust evidence of the adverse impact of comorbid depression on mortality among patients with DM. Large-scale intervention studies are needed to test whether decreasing the burden of comorbid depression in patients with Type 2 diabetes would decrease mortality rates.
